Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma

References

• Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005;6:93–102.
   PubMed Web of Science ®Google Scholar
• Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187–198.
   PubMed Web of Science ®Google Scholar
• Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13:219–227.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Antiemesis. version 2. (2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/ antiemesis.pdf. Accessed June 7, 2020.
   Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:3240–3261.
   PubMed Web of Science ®Google Scholar
• Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2006;27(suppl 5):v119–v133.
   Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Wang WS, Chiou TJ, Liu JH, et al. ESHAP as salvage therapy for refractory non-Hodgkin’s lymphoma: Taiwan experience. Jpn J Clin Oncol. 1999;29:33–37.
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–2947.
   PubMed Web of Science ®Google Scholar
• Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233–240.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 Mg Plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:242–249.
   PubMed Web of Science ®Google Scholar
• Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011;22:939–946.
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15:497–503.
   PubMed Web of Science ®Google Scholar
• Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–1367.
   PubMed Web of Science ®Google Scholar
• Olver IN, Grimison P, Chatfield M, et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer. 2013;21:1561–1568.
   PubMed Web of Science ®Google Scholar
• Adra N, Albany C, Brames MJ, et al. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier cancer research network study. Support Care Cancer. 2016;24:2837–2842.
   PubMed Web of Science ®Google Scholar
• Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol. 2012;30:3998–4003.
   PubMed Web of Science ®Google Scholar
• Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Saf. 1993;9:410–428.
   PubMed Web of Science ®Google Scholar
• Pieters RC, Vermorken JB, Gall HE, et al. A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy. Oncology. 1993;50:316–322.
   PubMed Web of Science ®Google Scholar
• Chevallier B, Marty M, Paillarse JM. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. ondansetron study group. Br J Cancer. 1994;70:1171–1175.
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to Standard Antiemetic Therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
   PubMed Web of Science ®Google Scholar
• McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.
   PubMed Web of Science ®Google Scholar
• Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and Granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National cancer institute of Canada clinical trials group. J Clin Oncol. 1998;16:1174–1178.
   PubMed Web of Science ®Google Scholar
• Goedhals L, Heron JF, Kleisbauer JP, et al. Control of delayed nausea and vomiting with granisetron Plus Dexamethasone or Dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol. 1998;9:661–666.
   PubMed Web of Science ®Google Scholar
• Tsukada H, Hirose T, Yokoyama A, et al. Randomised comparison of ondansetron Plus dexamethasone with Dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37:2398–2404.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Mori T, Kato J, et al. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2014;99:457–462.
   PubMed Web of Science ®Google Scholar